These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9058493)

  • 1. Effects of estrogen replacement therapy on thrombin generation.
    Pinto S; Bruni V; Rosati D; Prisco D; Costanzo M; Giusti B; Abbate R
    Thromb Res; 1997 Feb; 85(3):185-93. PubMed ID: 9058493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH; Krämer R; Kwee B; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
    Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
    J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.
    Bonduki CE; Lourenço DM; Motta EL; Soares JM; Haidar MA; Baracat EC
    Clinics (Sao Paulo); 2007 Oct; 62(5):553-60. PubMed ID: 17952314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormone substitution therapy. Side-effects and compliance of various therapeutic regimens].
    Perrone G; Barillaro F; Bazzoffi R; Capri O; Critelli C; Galoppi P; Grande S; Santoro G
    Minerva Ginecol; 1999 Mar; 51(3):53-8. PubMed ID: 10352534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.
    Kroon UB; Silfverstolpe G; Tengborn L
    Thromb Haemost; 1994 Apr; 71(4):420-3. PubMed ID: 8052956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
    Brosnan JF; Sheppard BL; Norris LA
    Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.
    Zegura B; Keber I; Sebestjen M; Koenig W
    Atherosclerosis; 2003 May; 168(1):123-9. PubMed ID: 12732395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of hormone substitution therapy on AT III in women in the climacteric].
    Enzelsberger H; Heytmanek H; Kurz C; Metka M
    Zentralbl Gynakol; 1991; 113(11):639-44. PubMed ID: 1656654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
    Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women.
    Rabbani LE; Seminario NA; Sciacca RR; Chen HJ; Giardina EG
    J Am Coll Cardiol; 2002 Dec; 40(11):1991-9. PubMed ID: 12475460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
    Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
    Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women.
    Bonduki CE; Lourenço DM; Baracat E; Haidar M; Noguti MA; da Motta EL; Lima GR
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):330-3. PubMed ID: 9539282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy.
    Cintron D; Beckman JP; Bailey KR; Lahr BD; Jayachandran M; Miller VM
    Maturitas; 2017 May; 99():59-65. PubMed ID: 28364870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.
    Cortellaro M; Nencioni T; Boschetti C; Ortolani S; Buzzi F; Francucci B; Caraceni MP; Abelli P; Polvani F; Zanussi C
    Eur J Clin Pharmacol; 1991; 41(6):555-9. PubMed ID: 1667755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.